Kristina Totland Carm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kristina Totland Carm has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Rolf Inge Skotheim
Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway; Department of Informatics, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
4 shared publications - Andreas M. Hoff
Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway
3 shared publications Anne Cathrine Bakken
Department of Molecular Oncology Institute for Cancer Research, Oslo University Hospital‐Radiumhospitalet Oslo Norway
3 shared publications- Ragnhild A. Lothe
Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
3 shared publications Karol Axcrona
Department of Molecular Oncology Institute for Cancer Research, Oslo University Hospital‐Radiumhospitalet Oslo Norway
2 shared publications- Mari Bogaard
Department of Pathology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
2 shared publications
Latest Publications
- Open Access
- 9 August 2022
- Published by Wiley in International Journal of Cancer
- Vol. 152 (5) , 945-951
Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer
Primary prostate cancer shows a striking intraorgan molecular heterogeneity, with multiple spatially separated malignant foci in the majority of patients. Metastatic prostate cancer, however, typically reveals more homogenous molecular profiles, suggesting a monoclonal origin of the metastatic lesions. Longitudinal mutational spectra, comparing multiple primary lesions with metastases from the same patients remain poorly defined. We have here analyzed somatic mutations in multisampled, spatio‐temporal biobanked lesions (38 samples from primary foci and 1 sample from each of 8 metastases from seven prostate cancer patients) applying a custom‐designed panel targeting 68 prostate cancer relevant genes. The metastatic samples were taken at time of primary surgery and up to 7 years later, and sampling included circulating tumor DNA in plasma or solid metastatic tissue samples. A total of 282 somatic mutations were detected, with a range of 0 to 25 mutations per sample. Although seven samples had solely private mutations, the remaining 39 samples had both private and shared mutations. Seventy‐four percent of mutations in metastases were not found in any primary samples, and vice versa, 96% of mutations in primary cancers were not found in any metastatic samples. However, for three patients, shared mutations were found suggesting the focus of origin, including mutations in AKT1, FOXA1, HOXB13, RB1 and TP53. In conclusion, the spatio‐temporal heterogeneous nature of multifocal disease is emphasized in our study, and underlines the importance of testing a recent sample in genomics‐based precision medicine for metastatic prostate cancer.
- 9 August 2022
- Published by Wiley in International Journal of Cancer
- Vol. 152 (5) , 945-951
Open AccessSomatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer
Primary prostate cancer shows a striking intraorgan molecular heterogeneity, with multiple spatially separated malignant foci in the majority of patients. Metastatic prostate cancer, however, typically reveals more homogenous molecular profiles, suggesting a monoclonal origin of the metastatic lesions. Longitudinal mutational spectra, comparing multiple primary lesions with metastases from the same patients remain poorly defined. We have here analyzed somatic mutations in multisampled, spatio‐temporal biobanked lesions (38 samples from primary foci and 1 sample from each of 8 metastases from seven prostate cancer patients) applying a custom‐designed panel targeting 68 prostate cancer relevant genes. The metastatic samples were taken at time of primary surgery and up to 7 years later, and sampling included circulating tumor DNA in plasma or solid metastatic tissue samples. A total of 282 somatic mutations were detected, with a range of 0 to 25 mutations per sample. Although seven samples had solely private mutations, the remaining 39 samples had both private and shared mutations. Seventy‐four percent of mutations in metastases were not found in any primary samples, and vice versa, 96% of mutations in primary cancers were not found in any metastatic samples. However, for three patients, shared mutations were found suggesting the focus of origin, including mutations in AKT1, FOXA1, HOXB13, RB1 and TP53. In conclusion, the spatio‐temporal heterogeneous nature of multifocal disease is emphasized in our study, and underlines the importance of testing a recent sample in genomics‐based precision medicine for metastatic prostate cancer.
- Open Access
- 18 June 2022
- Published by Wiley in Molecular Oncology
- Vol. 16 (15) , 2810-2822
In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis
Prognostic biomarkers for prostate cancer are needed to improve prediction of disease course and guide treatment decisions. However, biomarker development is complicated by the common multifocality and heterogeneity of the disease. We aimed to determine the prognostic value of candidate biomarkers transcriptional regulator ERG and related ETS family genes, while considering tumor heterogeneity. In a multisampled, prospective, and treatment‐naïve radical prostatectomy cohort from one tertiary center (2010–2012, median follow‐up 8.1 years), we analyzed ERG protein (480 patients; 2047 tissue cores), and RNA of several ETS genes in a subcohort (165 patients; 778 fresh‐frozen tissue samples). Intra‐ and interfocal heterogeneity was identified in 29% and 33% (ERG protein) and 39% and 27% (ETS RNA) of patients, respectively. ERG protein and ETS RNA was identified exclusively in a nonindex tumor in 31% and 32% of patients, respectively. ERG protein demonstrated independent prognostic value in predicting biochemical (P = 0.04) and clinical recurrence (P = 0.004) and appeared to have greatest prognostic value for patients with Grade Groups 4–5. In conclusion, when heterogeneity is considered, ERG protein is a robust prognostic biomarker for prostate cancer.
- 18 June 2022
- Published by Wiley in Molecular Oncology
- Vol. 16 (15) , 2810-2822
Open AccessIn situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis
Prognostic biomarkers for prostate cancer are needed to improve prediction of disease course and guide treatment decisions. However, biomarker development is complicated by the common multifocality and heterogeneity of the disease. We aimed to determine the prognostic value of candidate biomarkers transcriptional regulator ERG and related ETS family genes, while considering tumor heterogeneity. In a multisampled, prospective, and treatment‐naïve radical prostatectomy cohort from one tertiary center (2010–2012, median follow‐up 8.1 years), we analyzed ERG protein (480 patients; 2047 tissue cores), and RNA of several ETS genes in a subcohort (165 patients; 778 fresh‐frozen tissue samples). Intra‐ and interfocal heterogeneity was identified in 29% and 33% (ERG protein) and 39% and 27% (ETS RNA) of patients, respectively. ERG protein and ETS RNA was identified exclusively in a nonindex tumor in 31% and 32% of patients, respectively. ERG protein demonstrated independent prognostic value in predicting biochemical (P = 0.04) and clinical recurrence (P = 0.004) and appeared to have greatest prognostic value for patients with Grade Groups 4–5. In conclusion, when heterogeneity is considered, ERG protein is a robust prognostic biomarker for prostate cancer.
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e340
Molecular research on localized prostate cancer needs to take inter-focal heterogeneity into account
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e340
Molecular research on localized prostate cancer needs to take inter-focal heterogeneity into account
- Open Access
- 13 April 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (30) , 49133-49143
Novel transcription-induced fusion RNAs in prostate cancer
Novel transcription-induced fusion RNAs in prostate cancer Novel transcription-induced fusion RNAs in prostate cancer
- 13 April 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (30) , 49133-49143
Open AccessNovel transcription-induced fusion RNAs in prostate cancer
Novel transcription-induced fusion RNAs in prostate cancer Novel transcription-induced fusion RNAs in prostate cancer